Astrazeneca (AZN) Inventory (2009 - 2026)

Astrazeneca has reported Inventory for 18 years, with the latest figure at $6.9 billion in Q2 2026.

• On a quarterly basis, Inventory rose 7.19% year-over-year to $6.9 billion in Q2 2026; TTM through Jun 2026 was $6.9 billion, a 7.19% increase from a year earlier, with the FY2025 full-year figure at $6.6 billion, up 24.0% from the prior year.
• Inventory was $6.9 billion for Q2 2026 at Astrazeneca, up from $6.6 billion in the prior quarter.
• The five-year high for Inventory was $7.6 billion in Q1 2022, with the low at $4.7 billion in Q4 2022.
• Average Inventory over 5 years is $5.9 billion, with a median of $5.7 billion recorded in 2024.
• The largest YoY upside for Inventory was 78.21% in 2022 against a maximum downside of 51.77% in 2022.
• Over 5 years, Inventory stood at $4.7 billion in 2022, then increased by 15.43% to $5.4 billion in 2023, then fell by 2.51% to $5.3 billion in 2024, then rose by 24.0% to $6.6 billion in 2025, then increased by 5.72% to $6.9 billion in 2026.
• The last three Inventory figures came in at $6.9 billion (Q2 2026), $6.6 billion (Q1 2026), and $6.6 billion (Q4 2025), per Business Quant data.